Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
1.520
-0.035 (-2.25%)
Mar 31, 2025, 2:23 PM EDT - Market open
Adagene Revenue
In the year 2024, Adagene had annual revenue of $103.20K, down -99.43%. Adagene had revenue of $103.20K in the half year ending December 31, 2024, a decrease of -98.08%.
Revenue (ttm)
$103.20K
Revenue Growth
-99.43%
P/S Ratio
707.53
Revenue / Employee
$593
Employees
174
Market Cap
71.61M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ADAG News
- 7 days ago - Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 18 days ago - Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit - GlobeNewsWire
- 25 days ago - Adagene to Present at Leerink's Global Healthcare Conference 2025 - GlobeNewsWire
- 4 weeks ago - Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer - GlobeNewsWire
- 2 months ago - CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso, - GlobeNewsWire
- 2 months ago - Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - GlobeNewsWire
- 5 months ago - Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewsWire
- 6 months ago - Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewsWire